Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.760
+0.050 (2.92%)
Feb 21, 2025, 4:00 PM EST - Market closed
Immuneering Employees
Immuneering had 68 employees as of December 31, 2023. The number of employees decreased by 5 or -6.85% compared to the previous year.
Employees
68
Change (1Y)
-5
Growth (1Y)
-6.85%
Revenue / Employee
n/a
Profits / Employee
-$853,950
Market Cap
54.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
IMRX News
- 19 days ago - Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 weeks ago - Why Is Immuneering Stock Trading Higher On Tuesday? - Benzinga
- 2 months ago - Immuneering Launches Pancreatic Cancer Advisory Board - GlobeNewsWire
- 2 months ago - Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Benzinga
- 2 months ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma - GlobeNewsWire
- 3 months ago - Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - GlobeNewsWire